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SUMMARY
Aim: A substantial number of cardiovascular events are not prevented by statin
therapy, which is still regarded as the first-line therapy for hyperlipidaemia.
Insights into the prevalence of lipid abnormalities of statin-treated patients in Bel-
gium are lacking and may shed light on an unmet medical need for optimal use
of current lipid-lowering therapies. This study aims to assess the prevalence and
types of persistent lipid abnormalities in patients receiving statin therapy in a real-
life primary care setting in Belgium. Methods: This cross-sectional cohort study
was designed to estimate the prevalence of specific lipid abnormalities in statin-
treated patients in Belgium. Total cholesterol, low-density lipoprotein cholesterol
(LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides were
recorded from the patients’ medical record. Patient’s total cardiovascular risk and
corresponding lipid treatment goals were defined based on the recent European
Society of Cardiology/European Atherosclerosis Society recommendations. Results:
Overall, 56.2% of the statin-treated patients were not at goal for LDL-C. Low
HDL-C (< 40 mg dl1 in men, < 45 mg dl1 in women) and elevated triglycerides
(> 150 mg dl1) were seen in 16.3% and 29.0% of patients, respectively. Very
high-risk patients were more likely to have LDL-C not at goal (71.4% of them),
while 60.0% of high-risk patients and 34.1% of moderate-risk patients were not
at goal for LDL-C. Use of ezetimibe (10 mg) was strongly associated with meeting
LDL-C goals (OR 16.9, p < 0.0001). Conclusion: In Belgium, lipid abnormalities
remained highly prevalent despite statin treatment, with more than half of all
patients not reaching their LDL-C treatment goal. This finding clearly indicates that
more aggressive lipid-lowering treatment is required in clinical daily practice to
achieve the goals of the current guidelines.
What’s known
Despite the efficacy of current lipid-lowering
therapies, several studies have questioned whether
they are used in an optimal way. Various cross-
sectional studies have assessed the prevalence of
lipid abnormalities in different populations at risk.
However, these studies have substantial differences
in methodologies and definitions of target groups.
Limited information is available on the prevalence
of persistent dyslipidaemia in patients treated with
statins in a real-life setting.
What’s new
The Belgian part of the Dyslipidaemia International
Study provides insights in the prevalence and types
of persistent lipid abnormalities in patients
receiving statin therapy in a real-life setting in
Belgium, based on the most recent ESC/EAS
Guidelines for the management of dyslipidaemias.
The results clearly indicate that more aggressive
lipid-lowering treatment is required in clinical daily
practice to achieve the goals of the current
guidelines.
Introduction
Cardiovascular disease (CVD) is a leading cause of
mortality and will continue to be a major cause of
morbidity and mortality, as the prevalence of obesity,
diabetes and other risk factors continue to grow
(1,2). The cardiovascular-related mortality is largely
influenced by several modifiable risk factors such as
smoking, sedentary lifestyle and dyslipidaemia (3–5).
Statins (HMG-CoA reductase inhibitors) have
greatly advanced treatment of dyslipidaemia; for
every 39 mg dl1 reduction in low-density lipopro-
tein cholesterol (LDL-C), the risk of major cardio-
vascular events is decreased by 21% (3). Therefore,
statins are the first-line lipid-lowering therapy in
patients at risk of CVD (6). However, a substantial
number of clinical events are not prevented despite
statin therapy (7–9), which may be explained by
residual abnormalities in LDL-C, high-density lipo-
protein cholesterol (HDL-C) and triglycerides (9,10).
Despite the efficacy of current lipid-lowering ther-
apies, several studies have questioned whether they
are used in an optimal way (6,11). The European
Action on Secondary Prevention through Interven-
tion to Reduce Events (EUROASPIRE) III survey of
medical records from 2273 patients with coronary
heart disease, across 20 centres from 8 European
countries, found that 79% of all patients in Belgium
had total cholesterol ≥ 175 mg dl1 (12). This sug-
gests an unmet medical need for optimal use of cur-
rent lipid-lowering therapies or new therapies to
provide comprehensive lipid management.
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Various cross-sectional studies have assessed the
prevalence of lipid abnormalities in different pop-
ulations at risk (13–16). However, these studies
have substantial differences in methodologies and
definitions of target groups. Limited information
is available on the prevalence of persistent dyslip-
idaemia in patients treated with statins in a real-
life setting.
The objective of the Belgian part of the Dyslipida-
emia International Study (DYSIS) was to assess the
prevalence and types of persistent lipid abnormalities
in patients receiving statin therapy in a real-life set-
ting in Belgium, based on the most recent European
Society of Cardiology and the European Atheroscle-
rosis Society (ESC/EAS) Guidelines for the manage-
ment of dyslipidaemias (6).
Methods
Study design and population
The DYSIS-Belgium study is a cross-sectional cohort
study designed to estimate the prevalence of different
types of lipid abnormalities in statin-treated patients
in Belgium. Outpatients managed by their primary
care physician (PCP) were enrolled in the study if
they: (i) were on statin therapy for ≥ 3 months at
the time of assessment visits; (ii) were
aged ≥ 45 years; and (iii) had at least one fasting
lipid parameter available in their medical chart while
receiving statin therapy. Exclusion criteria included
active participation in a clinical study. Each physi-
cian was allowed to include up to 12 patients. A rep-
resentative sample of primary and secondary care
patients were enrolled based on the setting in which
patients with dyslipidaemia are usually treated. In
Belgium, treatment of dyslipidaemia is being handled
by essentially all general practitioners and therefore
all physicians included in the study were general
practitioners. The Ethical Committee of the Univer-
sity Hospital Brussels – Vrije Universiteit Brussel
approved the protocol. All patients provided written
informed consent prior to participation.
Data collection
All data were collected from clinical examination and
medical charts from single outpatient visits between
September 2011 and March 2012. Selection bias was
reduced by enrolling patients from consecutive visits
irrespective of the visit’s cause.
Data were submitted by paper or electronic case
report forms in local language to a central database,
and held and managed at the Institut f€ur Her-
zinfarktforschung Ludwigshafen at the university of
Heidelberg, Germany. A number of sites were visited
by the study monitor for source data verification.
Patient demographic data, serum lipid parameters
from the last test available within the previous
12 months for total cholesterol, LDL-C, HDL-C and
triglycerides were recorded. Only results from
patients who had been on statin therapy
for ≥ 3 months were included in the analyses.
Specific patient-related lipid targets and the rele-
vance of the different lipid parameters for the
physicians were also recorded. The ESC/EAS recom-
mendations were used to classify a patient’s risk and
to define the LDL-C goal as well as abnormalities of
HDL-C and triglycerides (6). Patients at very high
risk were defined as those with pre-existing CVD,
diabetes, chronic kidney disease (glomerular filtration
rate < 60 mL min1 1.73 m2) and/or Systematic
COronary Risk Evaluation (SCORE) ≥ 10%. LDL-C
treatment goal for these patients was < 70 mg dl1
or ≥ 50% LDL-C reduction if target goal cannot be
reached. High-risk patients were those with markedly
elevated single risk factors such as familial dyslipidae-
mias and severe hypertension and/or SCORE ≥ 5%
and < 10%. LDL-C treatment goal for these patients
was < 100 mg dl1. Moderate-risk patients were
defined as those with a SCORE between ≥ 1%
and < 5%. Many middle-aged subjects belong to this
risk category. Their corresponding LDL-C treatment
goal was < 115 mg dl1.
Clinical variables collected were demographic and
lifestyle information, anthropometric information,
medical history, blood pressure and serologic data
(fasting plasma glucose, haemoglobin A1c, lipids).
Information collected on lipid and cardiovascular
therapies included the name and daily dose of the
current statin, and whether the primary reason for
use was hypercholesterolaemia, as well as the name
and daily dose of the statin in use at the time of the
last blood test. Statin dose was categorised using a
potency calculation described elsewhere (17,18). In
brief, the potency of different statins was bench-
marked against six simvastatin doses: 5, 10, 20, 40,
80 and 160 mg day1. Each statin dose was given a
potency rating, ranging from 1 (= 5 mg day1) to 6
(= 160 mg day1). Use of other lipid-modifying
therapies (cholesterol absorption inhibitor, bile acid
sequesterants, fibrate, nicotinic acid) at visit and
before the previous blood test was recorded. Further-
more, treatments with anthihypertensives, antidiabet-
ics or antiplatelets were also recorded.
Statistical analysis
Categorical variables are presented as absolute num-
bers and percentages. Continuous variables are
reported as means with standard deviations or medi-
ans with 25th and 75th percentiles (interquartile
range) as appropriate.
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Multiple logistic regression analysis was performed
to detect factors independently associated with LDL-C,
HDL-C, and triglyceride abnormalities. Variables
included in the model were: age; sex; first grade family
history of premature CVD; current smoker; sedentary
lifestyle; alcohol consumption > 2 units per week;
body mass index (BMI) categorised as ≥ 30 kg m2
(obesity); waist circumference > 102 cm in men
or > 88 cm in women; hypertension; diabetes mell-
itus; ischaemic heart disease; cerebrovascular disease;
heart failure; peripheral artery disease; blood pressure
≥ 140/90 mmHg; 20–40 mg day1 vs. 10 mg day1
simvastatin equivalent; ≥ 80 mg day1 vs. 10 mg
day1 simvastatin equivalent; ezetimibe; and, physi-
cian’s specialty. A stepwise backward selection (alpha
= 0.05) was used to identify parameters associated
with dependent variables. All statistical comparisons
were two-tailed, and p < 0.05 was considered statisti-
cally significant. All analyses were performed with the
Statistical Analysing System, version 9.1 (SAS Institute
Inc., Cary, North Carolina). Patients who did not have




In total, 941 patients were recruited by 121 general
practitioners (GP) around Belgium (distribution of
GP’s across Belgium was 57.7% in Flanders, 35.0%
in Wallonia and 7.3% in Brussels). Patient character-
istics are presented in Table 1. Mean age of all
patients was 67.4  9.9 years. Sixty-one per cent of
the patients were at very high risk of cardiovascular
complications, 37.6% had pre-existing CVD, 54.0%
had metabolic syndrome and 31.0% were diabetic.
The most frequently used statin was simvastatin
(44.8%), followed by atorvastatin (25.8%) and rosu-
vastatin (21.0%). Notably, only 11.6% of patients
received additional lipid therapies to statins. Ezetim-
ibe (10 mg) was used by 7.2% of all patients; 3.3%
received it as a combination tablet with statin while
3.9% was using ezetimibe and a statin as two sepa-
rate tablets (data not shown).
Most of the patients were using lower dose statin
potencies (potency 1–4, equivalent to simvastatin 5–
40 mg day1) compared with higher dose statin
Table 1 Patient characteristics, risk categories and lipid parameters
All patients (N = 941) Men (N = 557) Women (N = 379)
Age (years) [mean  SD] 67.4  9.9 66.5  10.2 68.7  9.4
Caucasian (%) 99.5 99.8 99.1
Family Hx of premature CHD (%) 32.8 34.2 30.2
Current smokers (%) 11.8 14.6 7.9
Hypertension (%) 70.3 70.0 70.6
Systolic BP (mmHg) [mean  SD] 131.9  13.6 131.8  13.3 132.2  14.2
Diastolic BP (mmHg) [mean  SD] 78.0  7.9 78.4  7.8 77.5  7.9
Waist circumference (cm) [mean  SD] 99.7  14.4 103.7  13.3 93.8  14.0
BMI (kg m2) [mean  SD] 28.2  5.0 28.4  4.5 28.0  5.7
BMI>30 kg m2 (%) 28.9 28.4 30.1
CVD (%) 37.6 45.0 26.7
Diabetes mellitus (%) 31.0 34.9 25.1
Metabolic syndrome (IDF) (%) 54.0 56.6 50.5
ESC risk level (2011)
Very high-risk patient (%) 61.0 69.1 48.7
High-risk patient (%) 9.3 8.3 10.8
Moderate-risk patient (%) 20.0 14.7 28.0
Low-risk patient (%) 9.8 7.9 12.4
LDL-C (mg dl1) [mean  SD] 99.4  32.1 96.0  30.3 104.1  32.8
HDL-C (mg dl1) [mean  SD] 56.3  17.4 52.4  16.2 62.1  17.4
Total cholesterol (mg dl1) [mean  SD] 181.5  36.6 175.2  33.9 190.4  37.4
Triglycerides (mg dl1) [median (IQR)] 117.0 (86.0–161.0) 119.5 (88.0–165.5) 113.5 (85.0–154.0)
Fasting plasma glucose (mg dl1) [median (IQR)] 100.0 (90.0–116.0) 102.5 (92.0–120.0) 96.0 (88.0–108.0)
HbA1 c [%] in diabetics [median (IQR)] 6.7 (6.2–7.3) 6.7 (6.2–7.4) 6.7 (6.2–7.3)
CHD, coronary heart disease; BP, blood pressure; BMI, Body mass index; CVD, cardiovascular disease; DM, diabetes mellitus; IDF,
International Diabetes Federation; Very high risk = pre-existing CVD, diabetes, chronic kidney disease (glomerular filtration
rate < 60 ml min1 1.73 m2) and/or SCORE ≥ 10%. High risk = markedly elevated single risk factors and/or SCORE ≥ 5%
and < 10. Moderate risk = SCORE between ≥ 1% and < 5%. Low risk = SCORE < 1%.
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potencies (potency 5–6, equivalent to simvastatin
80–160 mg day1) (Figure 1). More specifically, in
non-very high risk patients, the most often used sta-
tin dose potency was 3 (44.4%), while very high-risk
patients were mostly treated with statin dose potency
4 (49.9%) (Figure 1).
Lipid parameters and CVD risk
The mean LDL-C in all patients was
99.4  32.1 mg dl1. More than half of all patients
(56.2%) had LDL-C not at goal according to the
2011 ESC/EAS guidelines. Complete results of serum
lipids are given in Table 2. Low HDL-C
(< 40 mg dl1 in men and < 45 mg dl1 in women)
and elevated triglycerides (> 150 mg dl1) were seen
in 16.3% and 29.0% of patients, respectively. More
patients at very high risk had LDL-C not at goal
(71.4% of them), while 60.0% of high-risk patients
and 34.1% of moderate-risk patients were not at goal
for LDL-C.
A high percentage of both diabetic patients
(73.8%) and patients with previous CVD (71.2%)
analysed separately had LDL-C not at goal
(≥ 70 mg dl1). A large proportion of patients with
a SCORE of more than 10% (without patients with
prior CVD and diabetes) were not at goal for LDL-C
(88.2%) (Table 3).
Examination of the distribution of serum lipid
abnormalities revealed that abnormally high LDL-C
was the most frequent lipid anomaly, either alone
(34.3%) or in combination with elevated triglycerides
(17.8%), low HDL-C (9.6%) or both (5.5%; Fig-
ure 2A). Elevated fasting triglycerides were most fre-
quent with elevated LDL-C, while low HDL-C was
seen most often with the combination of elevated
LDL-C and elevated triglycerides.
More specifically in very high-risk patients, only
16.4% displayed no lipid abnormalities, while 42.7%
had only abnormal LDL-C (Figure 2B). In non-very
high risk patients, almost half of these patients
Figure 1 Statin dose potency according to patients’ risk status. *Statin dose potency 1 is equivalent to Simvastatin
5 mg day1, potency 2 is equivalent to Simvastatin 10 mg day1, potency 3 is equivalent to Simvastatin 20 mg day1,
potency 4 is equivalent to Simvastatin 40 mg day1, potency 5 is equivalent to Simvastatin 80 mg day1 and potency 6 is
equivalent to Simvastatin ≥ 160 mg day1






(N = 85) Moderate risk (N = 176) Low risk (N = 80)
LDL-C not at goal [%]† 56.2 71.4 60.0 34.1 0.0
Low HDL-C
(< 40 [men]/45
[women] mg dl1) [%]
16.3 21.1 4.7 10.2 10.0
Elevated TG
(> 150 mg dl1) [%]
29.0 31.3 31.8 25.6 18.8
*Very High risk = CVD, Diabetes, and/or SCORE risk ≥10% (Chronic Kidney disease was not documented in DYSIS).
†LDL ≥ 115 mg dl1 in patients with SCORE risk 1–4%, LDL ≥ 100 mg dl1 in patients with SCORE risk 5–9%, LDL ≥ 70 mg dl1
in patients with CVD, DM, and/or SCORE risk ≥ 10%.
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(48.7%) had no lipid abnormalities but 21.1% of
them had LDL-C abnormalities (Figure 2C).
Multiple logistic regression analysis
Age ≥ 70 years, alcohol consumption of > 2 units
per week, diabetes, ischaemic heart disease and blood
pressure ≥ 140/90 mmHg were all positively associ-
ated with LDL-C abnormalities (Table 4). No use of
ezetimibe was very strongly, positively associated
with LDL-C abnormalities (OR 16.9, p < 0.0001).
Only ischaemic heart disease and diabetes were
positively associated with low HDL-C. Current







(N = 149) SCORE > 10% (N = 51)
LDL-C > 70 mg dl1 and
LDL-reduction < 50% [%]
61.2 71.2 73.8 88.2
Low HDL-C
(< 40 [men]/45 [women] mg dl1) [%]
27.3 17.8 26.2 3.9




Figure 2 Distribution of single and multiple combined lipid abnormalities. (A) all patients, (B) very high-risk patients
(CVD, Diabetes and/or SCORE ≥ 10%), and (C) non-very high risk patients (SCORE < 10%). ESC, European Society of
Cardiology; CVD, cardiovascular disease
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smoking, sedentary lifestyle, large waist circumfer-
ence and hypertension were positively associated with
elevated triglycerides. On the contrary, age ≥ 70 years
was strongly and negatively associated with elevated
triglycerides (Table 4).
Diabetes was the only factor positively associated
with LDL-C not at goal in combination with low
HDL-C and elevated triglycerides (OR 4.83,
p < 0.0001).
Discussion
In this Belgian observational study, we investigated
serum lipid goal achievement in statin-treated
patients stratified by their cardiovascular risk accord-
ing to the recent ESC/EAS guidelines (6). Here, we
have shown that only about 30% of all patients in
this study had no residual lipid abnormalities. Given
that the patients in this study were receiving statin
therapy, it was disappointing that LDL-C still
remained elevated in more than half of the patients.
Moreover, a large number of patients had abnormal
HDL-C and/or triglycerides, either alone or in com-
bination with other lipid parameters.
A number of cross-sectional epidemiologic studies
have also investigated the prevalence of lipid abnor-
malities and statin use (12,15,16,19–24). These stud-
ies, however, were limited to specific populations,
focused on specific lipid parameters such as LDL-C
or HDL-C, or had mixed patients with different
lipid-lowering therapies. With the current observa-
tional study, we analysed the prevalence of residual
dyslipidaemia in statin-treated patients in both pri-
mary and secondary prevention in Belgium. To our
knowledge, this is the first such study in Belgium
focused solely on statin users in a real-life setting.
Several parameters were shown to be clearly asso-
ciated with high LDL-C. For example, ischaemic
heart disease and diabetes were associated with LDL-
C not at goal. This illustrates that especially these
very high-risk patients need better or more powerful
treatment to obtain their corresponding target levels.
On the contrary, add-on therapy with ezetimibe
treatment was very strongly associated with low
LDL-C.
Serum lipid goal achievement in patients included
in this study was based on the most recent ESC/EAS
guidelines for the management of dyslipidaemias (6).
These guidelines were published around June 2011,
while this study started recruiting patients in October
2011. The implementation of recently published
guidelines may take some time to be implemented
into clinical practice. This observation can be rein-
forced by the fact that following analysis of the
Table 4 Multivariate analysis for predictors of therapeutic goal achievement
LDL-C not at goal* (70/100/
115 mg dl1)
Low HDL-C* (< 40 (m)/45
(w) mg dl1)
Elevated TG*
(> 150 mg dl1)
LDL-C not at goal and low
HDL-C and elevated TG*
OR (95% CI)* p-value* OR (95% CI)* p-value* OR (95% CI)* p-value* OR (95% CI)* p-value*
Age ≥ 70 years 2.090 (1.47–2.98) < 0.0001 n.s. n.s. 0.506 (0.35–0.74) 0.0004 n.s. n.s.
Current smoker n.s. n.s. n.s. n.s. 1.045 (1.05–2.96) 0.0335 n.s. n.s.
Sedentary lifestyle n.s. n.s. n.s. n.s. 1.458 (1.01–2.1) 0.0437 n.s. n.s.
Alcohol consumption > 2
units per week
1.459 (1.03–2.07) 0.0351 n.s. n.s. n.s. n.s. n.s. n.s.
Waist circumference > 102
(m)/> 88 cm (w)
n.s. n.s. n.s. n.s. 1.936 (1.33–2.83) 0.0006 n.s. n.s.
Hypertension n.s. n.s. n.s. n.s. 1.763 (1.16–2.67) 0.0076 n.s. n.s.
Diabetes mellitus 1.467 (1.00–2.15) 0.0496 3.077 (1.99–4.76) < 0.0001 n.s. n.s. 4.831 (2.33–10.0) < 0.0001
Ischaemic heart disease 2.026 (1.35–3.05) 0.0007 1.637 (1.04–2.59) 0.0352 n.s. n.s. n.s. n.s.
BP >140/90 mmHg
(systolic/diastolic)
1.680 (1.16–2.43) 0.0061 n.s. n.s. n.s. n.s. n.s. n.s.
No ezetimibe 16.9 (6.25–50) < 0.0001 n.s. n.s. n.s. n.s. n.s. n.s.
*Models contained the following variables: age, sex, 1st grade family history of premature CVD, current smoker, sedentary lifestyle, alcohol consumption > 2 units
per week, BMI ≥ 30 kg m2 (obesity), waist circumference > 102 cm in men/> 88 cm in women, hypertension, diabetes mellitus, ischaemic heart disease,
cerebrovascular disease, heart failure, peripheral artery disease, BP ≥ 140/90 mmHg (systolic/diastolic), 20–40 vs. 10 mg day1 Simvastatin equivalent, ≥ 80 vs.
10 mg day1 Simvastatin equivalent, Ezetimibe, Backward selection (alpha = 0.05) was done. m, men; w, women; BP, blood pressure; Card, cardiologist; Endo,
endocrinologist; Dia, diabetologist; Int, internist; Oth, other speciality; n.s., not significant (p > 0.05); OR, odds ratio; CI, confidence interval. Factors with odds ratios
(OR) > 1 indicate significant positive association with the lipid anomaly at the top of each column. Factors with OR < 1 indicate significant negative association
with the corresponding lipid anomaly. Non-significant associations are represented by n.s.
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current dataset based on the previous ESC guidelines
of 2007, still nearly 40% of all patients had LDL-C
above their corresponding target (data not shown).
Thus, with this study we have shown that real-life
daily practice is not yet in keeping with what is rec-
ommended in the guidelines. This, again, highlights
the importance of implementation programs because
it has been shown that disease outcome may be
favourably influenced by the thorough application of
clinical recommendations (6).
Lipid-lowering therapies
The average statin dose potency was 3–4 (simvastatin
equivalent 20–40 mg day1). The large number of
statin-treated patients with residual dyslipidaemia
may suggest the need for increasing (i) the use of
higher doses of statins or (ii) the use of combination
therapy. Earlier statin trials have concluded that the
proportional reduction in risk is mainly achieved by
the absolute reduction in LDL-C, and that more
intensive LDL-reduction yields further reductions in
risk (3,25). Currently, both the use of higher doses
of statins or combination therapy are well-validated
strategies to further reduce LDL.
Multivariate analysis did not indicate higher statin
dose to be associated with target achievement for
LDL-C. Moreover, it is well-known that high dose
statins are associated with an increased risk of myop-
athy (26). More importantly, a recent meta-analysis
of data from 5 statin trials has shown that intensive-
dose statin therapy was associated with an increased
risk of new-onset diabetes compared with moderate-
dose therapy (27).
In this study, use of alternative therapies com-
bined with statins was low. Despite the small number
of patients treated with ezetimibe (n = 68), multivar-
iate analysis indicated that treatment with ezetimibe
(10 mg) was strongly associated with LDL-C goal
achievement. However, the question remains whether
an additional LDL-C lowering using ezetimibe also
results in a reduction of cardiovascular events
(28,29), which might also partly explain the low
number of patients on ezetimibe in this study. The
results of the ongoing IMProved Reduction of Out-
comes: Vytorin Efficacy International Trial
(IMPROVE-IT) comparing ezetimibe plus simvasta-
tin with simvastatin monotherapy with regard to
CVD outcomes after acute coronary syndromes
should further elucidate the effect of ezetimibe on
CVD events (30).
Lipid levels and cardiovascular risk
Almost three-quarters of all patients included by the
121 primary care physicians had residual lipid abnor-
malities despite statin therapy, and more than half
had elevated LDL-C, either as a single anomaly or in
combination with either low HDL-C and/or elevated
triglycerides.
The analysis of the statin dose potencies according
to the patients’ risk status showed that very high-risk
patients were using more potent statins when com-
pared with non-very high risk statins. Despite their
more intense treatment, a large number of them
were not at goal for their LDL-C. More specifically,
of all diabetic patients in this study, nearly 74% of
them had LDL-C ≥ 70 mg dl1. This finding was
also reinforced by the fact that the presence of diabe-
tes was strongly associated with abnormal LDL-C in
the association analysis. Moreover, diabetes was the
only factor independently associated with LDL-C not
at goal in combination with low HDL-C and elevated
triglycerides. This confirms the mixed type of dyslip-
idaemia often seen in this specific population.
Limitations
Some limitations of our study should be mentioned.
Firstly, this was a cross-sectional, observational study
without any long-term outcome evaluations. Sec-
ondly, data analyses were based on patients’ medical
records. No blood sample collection or central evalu-
ation of the lipid parameters at the time of visit was
performed so measurement of lipid parameters may
not be standardised. This, however, truly reflected
the clinical practice. Primary care physicians willing
to participate in this study were recruited, which
may result in better outcomes as these physicians
were more motivated to treat their dyslipidaemia
patients. Finally, our study did not collect data on
the full patient lifestyle, including nutritional habits,
in-depth genetic predisposition to CVD (although
family history was assessed), or treatment compli-
ance. These variables also have some impact on the
patients’ lipid levels, so there is potential for residual
confounding because of these unmeasured or mis-
measured variables.
Conclusions
In this Belgian observational study, lipid abnormali-
ties were highly prevalent in statin-treated patients,
with only about 30% of patients having no residual
lipid abnormalities. More than half of all patients
had LDL-C not at goal, either as the only lipid
abnormality or combined with either abnormal
HDL-C or triglycerides or both. Most of the patients
in this study were very high-risk patients. Within this
patient risk group, more than 70% had abnormal
LDL-C despite the fact that they were receiving
higher statin doses compared with non-very high risk
patients. This finding clearly indicates that more
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aggressive lipid-lowering treatment is required in
clinical daily practice to achieve the goals of the cur-
rent guidelines.
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